Details

Autor(en) / Beteiligte

• Ostrowska, J
• Jakubczyk, M
• Niewada, M
• Lipka, I
• Petrova, G
• Tcharaktchiev, D
• Mitkova, Z
• Tsonev, S
• Verkauskiene, R
• Popovic Pejicic, S
• Vulic, D
• Seranic, A
• Pana, A
• Vasile Ileanu, B
• Došenovič Bonča, P
• Janša, K
• Valov, V
• Jokubauskiene, G
• Hałdaś, M
• Jusufovic, R
• Ciocirlan, R
• Stariha, J
• Russel-Szymczyk, M

Titel

Estimating The Cost of Diabetes-Related Cardiovascular Complications In Selected Central And Eastern European Countries

Ist Teil von

• Value in health, 2017-10, Vol.20 (9), p.A476

Ort / Verlag

Lawrenceville: Elsevier Science Ltd

Erscheinungsjahr

2017

Quelle

Applied Social Sciences Index & Abstracts (ASSIA)

Beschreibungen/Notizen

• OBJECTIVES: Cardiovascular complications (CVCs) in diabetes mellitus (DM) are important from clinical and economic perspective. Pragmatic search of literature demonstrated lack of cost data for Central and Eastern Europe (CEE), while the rapid health technology assessment (HTA) advancement requires substantiated information to guide decisions. We aimed to estimate the direct public payer medical costs of CVCs in Bulgaria, Lithuania, Poland, Republic of Srpska, Bosnia and Herzegovina (RSBH), Romania, and Slovenia. METHODS: The considered CVCs included: myocardial infarction (MI), unstable (UA)/stable angina pectoris, peripheral vascular disease (PVD), heart failure (HF), stroke, transient ischemic attack, painful neuropathy, retinopathy, end-stage renal disease (ESRD), and diabetic foot. Local clinical and HTA experts provided data (based on experience, literature, databases, etc.) on epidemiology, rate/prevalence of CVCs, mortality (at the event and during follow-up), and cost (event, 1st year, subsequent years; split into hospitalizations, other procedures, and drugs) by filling a unified questionnaire. All doubts and inconsistencies were discussed. RESULTS: The total cost (all costs expressed in Euros per annum) amounted to 1,231 million in Poland, 581 million in Romania, 103 million in Bulgaria, 76 million in Slovenia, 47 million in RSBH, and 26 million in Lithuania (hospitalizations only, resulting in possible underestimation). The cost per single DM patient was similar for Romania, Slovenia, Poland, and RSBH (range 586-759) and lower in Lithuania (267.6) and Bulgaria (218.5). The average (for all countries, except Lithuania) share of individual CVCs in total cost is largest for HF (20.9%), followed by around 13% for MI, UA, stroke, and ESRD. CONCLUSIONS: Our study is the first attempt to assess the cost of DM-related CVCs in CEE and can be used in economic modelling. CVCs form an important financial burden for public payers. Collecting data for several countries is challenging as available information differs, but it allows quality checks by juxtaposing the input parameters.